AR119057A1 - Compuestos de 1-oxo-isoindolin-5-carboxamida sustituida, composiciones de estos y métodos de tratamiento con dichos compuestos - Google Patents
Compuestos de 1-oxo-isoindolin-5-carboxamida sustituida, composiciones de estos y métodos de tratamiento con dichos compuestosInfo
- Publication number
- AR119057A1 AR119057A1 ARP200101539A ARP200101539A AR119057A1 AR 119057 A1 AR119057 A1 AR 119057A1 AR P200101539 A ARP200101539 A AR P200101539A AR P200101539 A ARP200101539 A AR P200101539A AR 119057 A1 AR119057 A1 AR 119057A1
- Authority
- AR
- Argentina
- Prior art keywords
- substituted
- compounds
- unsubstituted
- isoindoline
- oxo
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Reivindicación 1: Un compuesto caracterizado por la fórmula (1), o una sal aceptable desde el punto de vista farmacéutico, un tautómero, un isotopólogo o un estereoisómero de este, en donde: R¹ es C₁₋₃ alquilo o C₁₋₃ fluoroalquilo; R² es C₁₋₆ alquilo sustituido o no sustituido, C₃₋₁₀ cicloalquilo sustituido o no sustituido, heterociclilo de 3 a 6 miembros sustituido o no sustituido, C₆₋₁₀ arilo sustituido o no sustituido, o heteroarilo de 5 a 10 miembros sustituido o no sustituido; R³ es H; R⁴ es halógeno; y n es 0 - 3.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962855619P | 2019-05-31 | 2019-05-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR119057A1 true AR119057A1 (es) | 2021-11-17 |
Family
ID=73551319
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP200101539A AR119057A1 (es) | 2019-05-31 | 2020-05-29 | Compuestos de 1-oxo-isoindolin-5-carboxamida sustituida, composiciones de estos y métodos de tratamiento con dichos compuestos |
Country Status (16)
Country | Link |
---|---|
US (2) | US11306101B2 (es) |
EP (1) | EP3976595A4 (es) |
KR (1) | KR20220016167A (es) |
CN (2) | CN114957212B (es) |
AR (1) | AR119057A1 (es) |
AU (1) | AU2020282748A1 (es) |
BR (1) | BR112021022758A2 (es) |
CA (1) | CA3136753A1 (es) |
CL (1) | CL2021003134A1 (es) |
CO (1) | CO2021015624A2 (es) |
IL (1) | IL288278A (es) |
MX (1) | MX2021014350A (es) |
PE (1) | PE20220569A1 (es) |
SG (1) | SG11202112872YA (es) |
TW (1) | TW202110819A (es) |
WO (1) | WO2020243379A1 (es) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020243379A1 (en) | 2019-05-31 | 2020-12-03 | Celgene Corporation | Substituted 1-oxo-isoindoline-5-carboxamide compounds, compositions thereof, and methods of treatment therewith |
CN112679421A (zh) * | 2021-01-04 | 2021-04-20 | 都创(上海)医药科技股份有限公司 | 一种(r)-3-氯吡啶基-2-三氟乙胺盐酸盐的合成方法 |
WO2022152821A1 (en) | 2021-01-13 | 2022-07-21 | Monte Rosa Therapeutics Ag | Isoindolinone compounds |
BR112023023076A2 (pt) * | 2021-05-06 | 2024-01-30 | Celgene Corp | Métodos de tratamento com n-((r)-1-(3-cloropiridin-2-il)-2,2,2-trifluoroetil)-2-((s)-2,6-dioxopiperidin-3-il)-1-oxoisoindolina-5-carboxamida |
WO2022257897A1 (en) * | 2021-06-08 | 2022-12-15 | Hangzhou Glubio Pharmaceutical Co., Ltd. | Isoindolinone compounds, and uses thereof |
CN115504963A (zh) * | 2021-06-22 | 2022-12-23 | 苏州开拓药业股份有限公司 | 一种c-Myc蛋白降解剂 |
WO2023178181A1 (en) | 2022-03-17 | 2023-09-21 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
WO2023244818A1 (en) * | 2022-06-16 | 2023-12-21 | Monte Rosa Therapeutics, Inc. | Molecular glue degraders and methods of using the same |
WO2023244815A1 (en) * | 2022-06-16 | 2023-12-21 | Monte Rosa Therapeutics, Inc. | Molecular glue degraders and methods of using the same |
WO2024027694A1 (zh) * | 2022-08-01 | 2024-02-08 | 苏州开拓药业股份有限公司 | 一种蛋白降解剂 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7091353B2 (en) | 2000-12-27 | 2006-08-15 | Celgene Corporation | Isoindole-imide compounds, compositions, and uses thereof |
JP5578785B2 (ja) | 2005-08-31 | 2014-08-27 | セルジーン コーポレイション | イソインドール−イミド化合物及びそれを含有する組成物及びそれの使用法 |
US8877780B2 (en) | 2006-08-30 | 2014-11-04 | Celgene Corporation | 5-substituted isoindoline compounds |
ZA200901078B (en) * | 2006-08-30 | 2010-06-30 | Celgene Corp | 5-substituted isoindoline compounds |
WO2017007612A1 (en) * | 2015-07-07 | 2017-01-12 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
WO2020243379A1 (en) | 2019-05-31 | 2020-12-03 | Celgene Corporation | Substituted 1-oxo-isoindoline-5-carboxamide compounds, compositions thereof, and methods of treatment therewith |
-
2020
- 2020-05-29 WO PCT/US2020/035043 patent/WO2020243379A1/en unknown
- 2020-05-29 AR ARP200101539A patent/AR119057A1/es unknown
- 2020-05-29 CN CN202210612012.4A patent/CN114957212B/zh active Active
- 2020-05-29 US US16/887,766 patent/US11306101B2/en active Active
- 2020-05-29 MX MX2021014350A patent/MX2021014350A/es unknown
- 2020-05-29 PE PE2021001963A patent/PE20220569A1/es unknown
- 2020-05-29 EP EP20812650.8A patent/EP3976595A4/en active Pending
- 2020-05-29 KR KR1020217042866A patent/KR20220016167A/ko unknown
- 2020-05-29 BR BR112021022758A patent/BR112021022758A2/pt unknown
- 2020-05-29 SG SG11202112872YA patent/SG11202112872YA/en unknown
- 2020-05-29 AU AU2020282748A patent/AU2020282748A1/en active Pending
- 2020-05-29 TW TW109117973A patent/TW202110819A/zh unknown
- 2020-05-29 CN CN202080040212.6A patent/CN114269729A/zh active Pending
- 2020-05-29 CA CA3136753A patent/CA3136753A1/en active Pending
-
2021
- 2021-11-21 IL IL288278A patent/IL288278A/en unknown
- 2021-11-22 CO CONC2021/0015624A patent/CO2021015624A2/es unknown
- 2021-11-24 CL CL2021003134A patent/CL2021003134A1/es unknown
-
2022
- 2022-03-09 US US17/690,921 patent/US20220213115A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20200377512A1 (en) | 2020-12-03 |
MX2021014350A (es) | 2022-02-21 |
AU2020282748A1 (en) | 2021-12-09 |
IL288278A (en) | 2022-01-01 |
EP3976595A4 (en) | 2023-01-04 |
US11306101B2 (en) | 2022-04-19 |
CN114957212A (zh) | 2022-08-30 |
CO2021015624A2 (es) | 2022-02-28 |
JP2022534979A (ja) | 2022-08-04 |
CL2021003134A1 (es) | 2022-07-01 |
SG11202112872YA (en) | 2021-12-30 |
KR20220016167A (ko) | 2022-02-08 |
PE20220569A1 (es) | 2022-04-20 |
CA3136753A1 (en) | 2020-12-03 |
EP3976595A1 (en) | 2022-04-06 |
TW202110819A (zh) | 2021-03-16 |
US20220213115A1 (en) | 2022-07-07 |
BR112021022758A2 (pt) | 2022-03-22 |
CN114269729A (zh) | 2022-04-01 |
WO2020243379A1 (en) | 2020-12-03 |
CN114957212B (zh) | 2024-05-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR119057A1 (es) | Compuestos de 1-oxo-isoindolin-5-carboxamida sustituida, composiciones de estos y métodos de tratamiento con dichos compuestos | |
AR114803A1 (es) | Compuestos de 4-aminoisoindolin-1,3-diona sustituida, composiciones de estos y métodos de tratamiento con dichos compuestos | |
AR114244A1 (es) | Compuestos que degradan efgr útiles en el tratamiento del cáncer | |
AR109349A1 (es) | Compuestos y usos | |
AR110405A1 (es) | Compuestos | |
AR108812A1 (es) | Proceso para preparar un derivado de piridona policíclica sustituida y cristal del mismo | |
AR114793A1 (es) | Moduladores de enzimas modificadoras de metilo, composiciones y usos de los mismos | |
AR107973A1 (es) | 6-hidroxi-4-oxo-1,4-dihidropirimidin-5-carboxamidas como agonista de apj | |
AR116283A1 (es) | Inhibidores del sarcómero cardíaco | |
AR093818A1 (es) | Compuesto de 1-(bencil sustituido)piperazina sustituida | |
AR113929A1 (es) | Compuestos heterocíclicos | |
AR097082A1 (es) | Compuestos terapéuticamente activos y sus métodos de uso | |
AR109711A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
AR104880A1 (es) | MODULADORES DE ROR GAMMA (RORg) | |
CO2022008968A2 (es) | Nuevos derivados de metilquinazolinona | |
AR111494A1 (es) | Compuestos de anilinoquinazolina c₅ y su uso en el tratamiento del cáncer | |
AR109776A1 (es) | Compuestos de p2x₃ y/o p2x₂/₃ y métodos | |
AR119376A1 (es) | Compuestos heterocíclicos | |
AR117037A1 (es) | Compuestos pirazol para el tratamiento de enfermedades autoinmunitarias | |
AR116713A1 (es) | COMPUESTOS DE IMIDAZOLINDIONA COMO REGULADORES DE CANALES Kv3 | |
AR112463A1 (es) | Derivados de propanamina para tratar el dolor y estados relacionados con dolor | |
AR116428A1 (es) | Compuestos de 6-fluoro-2-metilbenzo[d]tiazol-5-ilo | |
AR123241A1 (es) | Derivados de espiropiperidinilo sustituidos con heteroarilo y usos farmacéuticos de los mismos | |
AR096161A1 (es) | Derivados de triazina | |
AR112695A1 (es) | Inhibidores de cdpk1, composiciones y métodos relacionados con los mismos |